VA awards $2.1M for Lenalidomide to Excelan Pharmaceuticals, ensuring pharmaceutical supply

Contract Overview

Contract Amount: $2,125,992 ($2.1M)

Contractor: Exelan Pharmaceuticals Inc

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-01-15

End Date: 2027-01-14

Contract Duration: 364 days

Daily Burn Rate: $5.8K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: VA TUCSON LENALIDOMIDE DO

Place of Performance

Location: BOCA RATON, PALM BEACH County, FLORIDA, 33432

State: Florida Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $2.1 million to EXELAN PHARMACEUTICALS INC for work described as: VA TUCSON LENALIDOMIDE DO Key points: 1. Contract value of $2.1M for pharmaceutical preparations. 2. Excelan Pharmaceuticals Inc. is the awardee. 3. Competition method is Full and Open. 4. Sector is Pharmaceuticals, a critical area for healthcare.

Value Assessment

Rating: good

The contract value of $2.1M appears reasonable for the specified pharmaceutical product. Benchmarking against similar contracts for Lenalidomide would provide a more precise assessment of value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating a robust price discovery process. This method allows multiple vendors to bid, potentially leading to competitive pricing.

Taxpayer Impact: Full and open competition generally benefits taxpayers by driving down costs through market forces.

Public Impact

Ensures continued access to a critical medication for veterans. Supports the pharmaceutical manufacturing sector. Provides stability for the awarded vendor, Excelan Pharmaceuticals Inc.

Waste & Efficiency Indicators

Waste Risk Score: 58 / 10

Warning Flags

Potential for price fluctuations in future contract renewals.
Dependence on a single supplier for this specific medication.

Positive Signals

Awarded through full and open competition.
Long-term contract duration provides supply stability.

Sector Analysis

This contract falls within the Pharmaceutical Preparation Manufacturing sector, which is vital for healthcare services. Spending in this sector is consistently high due to the essential nature of medications.

Small Business Impact

The data does not indicate if small businesses were involved in this specific award or if they are part of the supply chain for Excelan Pharmaceuticals Inc.

Oversight & Accountability

The Department of Veterans Affairs is responsible for oversight. The BPA Call award mechanism suggests adherence to pre-established agreements, implying some level of prior vetting.

Related Government Programs

Pharmaceutical Preparation Manufacturing
Department of Veterans Affairs Contracting
Department of Veterans Affairs Programs

Risk Flags

Potential for price increases in subsequent contract periods.
Reliance on a single awardee for a critical drug.
Need for ongoing market research to ensure competitive pricing.
Vulnerability to supply chain disruptions.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $2.1 million to EXELAN PHARMACEUTICALS INC. VA TUCSON LENALIDOMIDE DO

Who is the contractor on this award?

The obligated recipient is EXELAN PHARMACEUTICALS INC.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $2.1 million.

What is the period of performance?

Start: 2026-01-15. End: 2027-01-14.

What is the historical pricing trend for Lenalidomide from this vendor or similar vendors?

Analyzing historical pricing data for Lenalidomide from Excelan Pharmaceuticals Inc. and comparable vendors is crucial. This would reveal if the current award reflects competitive market rates or if there's an opportunity for cost savings through further negotiation or competition in future solicitations. Understanding price trends helps ensure the VA is obtaining the best value for taxpayer dollars.

Are there any supply chain risks associated with Excelan Pharmaceuticals Inc. for this critical medication?

Assessing supply chain risks involves evaluating Excelan Pharmaceuticals Inc.'s manufacturing capacity, raw material sourcing, and any past performance issues. Given Lenalidomide's importance, disruptions could significantly impact veteran care. Proactive risk mitigation strategies, such as identifying alternative suppliers or maintaining strategic inventory levels, are essential to ensure uninterrupted availability.

How does the effectiveness of Lenalidomide, as supplied under this contract, compare to alternatives for veteran patient outcomes?

While this contract focuses on procurement, the ultimate effectiveness is measured by patient outcomes. The VA should monitor clinical data and veteran feedback to ensure the medication supplied meets efficacy standards. Comparing outcomes with alternative treatments, where applicable, can inform future formulary decisions and ensure veterans receive the most beneficial therapies.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 370 W CAMINO GARDENS BLVD STE 204, BOCA RATON, FL, 33432

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $2,125,992

Exercised Options: $2,125,992

Current Obligation: $2,125,992

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Parent Contract

Parent Award PIID: 36C26226A0006

IDV Type: BPA

Timeline